MarketVIEW: Cytomegalovirus vaccines (CAT: VAMV014)

Product Name : MarketVIEW: Cytomegalovirus vaccines
Description : Global vaccine commercial opportunity assessment
Contents : Executive presentation + forecast model
Therapeutic Area : Novel vaccines
Publication date : April 2014
Catalogue No : VAMV014

Background

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus.

Vaccine manufacturers are currently pursuing both therapeutic (TX) and prophylatic (PX ) CMV vaccine approaches. The most advanced program is Sanofi Pasteur’s gB vaccine (+ MF59 adjuvant) where protective efficacy has been shown in post-partum women (Phase II). Other notable approaches are Vical’s (Astellas) VCL-CB01 (ASP0113) DNA-based approach in HSCT seropositive recipients (Phase III) to be completed September 2016.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted, which in turn are influenced by vaccine mechanism of action and vaccinee serostatus.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Cytomegalovirus vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

Published April 2014 (CAT No: VAMV014)

****This product is composed of a model and summary presentation

Executive summary
Key model outputs
CMV preconception vaccine: available market ($000s) to 2035
CMV transplant vaccine: available market ($000s) to 2035
CMV preconception vaccine: demand (000s doses) to 2035
CMV transplant vaccine: demand (000s doses) to 2035
CMV preconception vaccine: coverage scenarios
CMV vaccine: modelling assumptions/rationale
The role of CMV vaccine(s)
Target populations: CMV preconception vaccine
Target populations: CMV transplant vaccine
Target groups by serological risk profile
Pricing: CMV preconception vaccine
Pricing: CMV transplant vaccine
Target product profile: CMV preconception vaccine
Target product profile: CMV transplant vaccine
Key commercial model assumptions: preconception vaccine
Key commercial model assumptions: transplant vaccine
Markets included in the model
Model forecast comparisons: June 2010 v current
CMV vaccines: R&D pipeline
Competitor landscape: overview
Vical/Astellas: TransVax and CyMVectin
GSK: preconception CMV vaccine
Novartis/AlphaVax: alphavirus replicon CMV vaccine
Sanofi Pasteur: CMV gB vaccine
Other vaccine candidates
Vaccine pipeline summary
Estimated launch dates: vaccines + mAbs
CMV: review of current epidemiology
Epidemiology: transplants
Epidemiology: congenital CMV infection
Appendix I: Quantifying CMV populations
Methodology: HDTST populations (by age and serostatus)
Methodology: solid organ transplant populations (by age and serostatus)
Methodology: preconception vaccine
Other supporting data
Prevalence of CMV in the US general population
Prevalence of CMV in other general populations.
Prevalence of CMV in transplant donors and recipients
AIDS patients with CMV retinitis
Prevalence of CMV in pregnant populations
Symptomatic newborns
Management of CMV disease after solid organ transplantation
Management of CMV infection in HSCT
Use of prophylactic/pre-emptive antivirals in HSCTs
Management of CMV retinitis in patients with AIDS
Treatment of congenital CMV in newborns
References/bibliography
About VacZine Analytics
Disclaimer

PAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)
Title sheet
Scenario definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME – HIGH
VALUE SUMMARY
VOLUME SUMMARY
Preconception vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Transplant vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Source material
HSCTs by serostatus
Forecast HSCTs
Forecast HSCTs
Kidney and Liver TX base
Continued.....
Forecast Kidney TX
Forecast liver Tx
SOT by serostatus
Populations
Back page
About VacZine Analytics
Disclaimer
2. National Vital Statistics Reports, Volume 60, Number 1, November 3, 201.
12. Clinicaltrials.gov